Identification

Name
Sodium bicarbonate
Accession Number
DB01390
Type
Small Molecule
Groups
Approved
Description

Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.

Structure
Thumb
Synonyms
  • Baking soda
  • Bicarbonate of soda
  • Carbonic acid monosodium salt
  • e 500
  • e-500
  • e500
  • NaHCO3
  • Natriumhydrogenkarbonat
  • Sodium acid carbonate
  • Sodium bicarbonate
  • Sodium hydrogen carbonate
  • Sodium hydrogencarbonate
External IDs
B1654 / E-500(II) / INS NO.500(II) / INS-500(II)
Active Moieties
NameKindUNIICASInChI Key
Carbon dioxideunknown142M471B3J124-38-9CURLTUGMZLYLDI-UHFFFAOYSA-N
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
800 Sodium Bicarbonate PowderPowder, for solution650 gHemodialysisBaxter Laboratories1988-12-31Not applicableCanada
BibagPowder, for solution650 gHemodialysisFresenius Medical Care Deutchland Gmbh2009-12-10Not applicableCanada
Bicarb Hemodial Conc 81.25gm/lLiquid81.25 gHemodialysisBicarbolyte Corporation1986-12-311998-06-08Canada
Bicarbolyte Bicar Hemodialysis ConcLiquid72 gHemodialysisBicarbolyte Corporation1986-12-311998-06-08Canada
Bicarbonate Conc Mb-330 Pwr 650mg/pckPowder650 gHemodialysisRenal Systems, Division Of Minntech Corp.1985-12-311998-11-02Canada
Bicarbonate Concentrate 4105Liquid80.68 gHemodialysisBaxter Laboratories1988-12-312002-08-01Canada
Bicarbonate Concentrate B38Solution80.7 gHemodialysisChief Medical Supplies Ltd2005-07-04Not applicableCanada
Bicarbonate Concentrate D17000Solution81.3 gHemodialysisBaxter Laboratories1986-12-31Not applicableCanada
BicartPowder720 gHemodialysisBaxter Laboratories2013-09-26Not applicableCanada
BicartPowder1250 gHemodialysisBaxter Laboratories2013-10-22Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sodium BicarbonateInjection, solution75 mg/1mLIntravenousHospira, Inc.2006-05-182008-10-01Us
Sodium BicarbonateInjection, solution42 mg/1mLIntravenousHospira, Inc.2017-01-012017-01-01Us
Sodium BicarbonateInjection84 mg/1mLIntravenousRemedy Repack2018-01-122018-03-08Us
Sodium BicarbonateInjection, solution84 mg/1mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Sodium BicarbonateInjection, solution84 mg/1mLIntravenousHospira, Inc.2006-05-182009-07-01Us
Sodium BicarbonateInjection84 mg/1mLIntravenousInternational Medication Systems, Limited2000-06-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
After Bite KidsLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUs
After Bite SensitiveLiquid5 g/100gTopicalTender Corporation2014-11-26Not applicableUs
After Bite the Itch EraserLiquid50 mg/1mLTopicalTender Corporation2014-09-02Not applicableUs
After Bite The Itch Eraser KIDSLiquid5 g/100gTopicalTender Corporation2014-11-262014-11-26Us
After Bite The Itch Eraser KIDSLiquid5 g/100gTopicalTender Corporation2014-11-252014-11-25Us
Anti-EmpachoLiquid525 mg/15mLOralMenper Distributors2012-02-21Not applicableUs
Arm and Hammer Baking SodaPowder, for solution1 g/1gOralChurch & Dwight Company, Inc.2000-01-01Not applicableUs
Arm and Hammer Baking SodaPowder, for solution1 g/1gOralChurch & Dwight Company, Inc.2018-02-02Not applicableUs
Assured Bug Bite ReliefLiquid5 g/100gTopicalShanghai Weierya Daily Chemicals Factory2015-11-10Not applicableUs
Assured Bug Bite ReliefLiquid5 g/100mLTopicalHuijing (Shanghai) Bio-tech Co., Ltd2017-08-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Accusol 35 K0Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + Magnesium chloride (0.136 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Accusol 35 K2Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.199 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies LtdNot applicableNot applicableCanada
Accusol 35 K4Sodium bicarbonate (12.9 g) + Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.398 g) + Sodium Chloride (7.66 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Alka SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralSalimex, S.A.2012-10-10Not applicableUs
Alka Seltzer EvtSodium bicarbonate (1.916 g) + Acetylsalicylic acid (325 mg) + Citric Acid (1 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1977-12-31Not applicableCanada
Alka Seltzer FlavouredSodium bicarbonate (1.71 g) + Acetylsalicylic acid (325 mg) + Citric Acid (1.22 g)Tablet, effervescentOralMiles Inc. Pharmaceutical Division1986-12-311996-09-09Canada
Alka Seltzer OriginalSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)TabletOralNavajo Manuracturing Company2016-09-16Not applicableUs
Alka-SeltzerSodium bicarbonate (1916 mg) + Acetylsalicylic acid (325 mg) + Citric Acid (1000 mg)Tablet, effervescentOralBayer1995-12-31Not applicableCanada
Alka-SeltzerSodium bicarbonate (1916 mg/1) + Acetylsalicylic acid (325 mg/1) + Citric Acid (1000 mg/1)Tablet, effervescentOralLil' Drug Store Products, Inc.2000-01-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
8.4% Sodium BicarbonateSodium bicarbonate (84 mg/1mL)Injection, solutionIntravenousHF Acquisition Co. LLC, DBA HealthFirst2018-09-01Not applicableUs
Adea GargleSodium bicarbonate (36.2 g/100mg) + D-Xylitol (5 g/100mg)Tablet, chewableOralK2resource Co., Ltd.2018-03-01Not applicableUs
Adea GargleSodium bicarbonate (36.2 g/100mg) + D-Xylitol (5 g/100mg)Tablet, chewableOralK2resource Co., Ltd.2018-03-012018-04-01Us
Assured Bug Bite ReliefSodium bicarbonate (5 g/100g)LiquidTopicalShanghai Weierya Daily Chemicals Factory2015-11-10Not applicableUs
CvsSodium bicarbonate (22.2 mg/.1g) + Sodium bicarbonate (22.8 mg/100mg) + Sodium Chloride (77.8 mg/.1g) + Sodium Chloride (77.8 mg/100mg)KitCVS Health2014-07-01Not applicableUs
CvsSodium bicarbonate (22.8 mg/100mg) + Sodium Chloride (77.8 mg/100mg)KitCVS PHARMACY2016-03-252016-03-25Us
CvsSodium bicarbonate (22.8 mg/100mg) + Sodium Chloride (77.8 mg/100mg)KitCVS PHARMACY2017-04-242017-04-25Us
CvsSodium bicarbonate (22.2 mg/.1g) + Sodium bicarbonate (22.8 mg/100mg) + Sodium Chloride (77.8 mg/.1g) + Sodium Chloride (77.8 mg/100mg)KitCVS Health2014-07-01Not applicableUs
CvsSodium bicarbonate (22.8 mg/100mg) + Sodium Chloride (77.8 mg/100mg)PowderNasalCVS Health2013-06-01Not applicableUs
Kettle Neti PotSodium bicarbonate (700 mg/1) + Sodium Chloride (2300 mg/1)Powder, for solutionOralCardinal Health 414, Llc2013-04-01Not applicableUs
Categories
UNII
8MDF5V39QO
CAS number
144-55-8
Weight
Average: 84.0066
Monoisotopic: 83.982338573
Chemical Formula
CHNaO3
InChI Key
UIIMBOGNXHQVGW-UHFFFAOYSA-M
InChI
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
IUPAC Name
sodium hydrogen carbonate
SMILES
[Na+].OC([O-])=O

Pharmacology

Indication

Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.

Associated Conditions
Pharmacodynamics

Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.

Mechanism of action

Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]

TargetActionsOrganism
AHydrogen ions
neutralizer
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Sodium bicarbonate.
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Sodium bicarbonate.
2,5-Dimethoxy-4-ethylamphetamineSodium bicarbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
2,5-Dimethoxy-4-ethylthioamphetamineSodium bicarbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.
3,4-MethylenedioxyamphetamineSodium bicarbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.
4-Bromo-2,5-dimethoxyamphetamineSodium bicarbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Sodium bicarbonate.
AcepromazineSodium bicarbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineSodium bicarbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetaminophenSodium bicarbonate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

Synthesis Reference

Alan B. Gancy, Rustom P. Poncha, "Production of low bulk density product from sodium bicarbonate by the use of an inert gas stream." U.S. Patent US3984527, issued August, 1922.

US3984527
General References
Not Available
External Links
KEGG Drug
D01203
KEGG Compound
C12603
PubChem Compound
516892
PubChem Substance
46507049
ChemSpider
8609
ChEBI
32139
ChEMBL
CHEMBL1353
Therapeutic Targets Database
DAP000128
PharmGKB
PA451375
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sodium_bicarbonate
ATC Codes
B05XA02 — Sodium bicarbonateB05CB04 — Sodium bicarbonate
AHFS Codes
  • 40:08.00 — Alkalinizing Agents
  • 56:04.00 — Antacids and Adsorbents
  • 40:34.00* — Hemodialysis Solution
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceTransplantation, Kidney1
0CompletedTreatmentPulmonary Ventilation1
0Not Yet RecruitingTreatmentEdema of the cerebrum / Saline Solution, Hypertonic1
1CompletedBasic ScienceCystic Fibrosis (CF)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionChronic Kidney Disease (CKD)1
1CompletedTreatmentAcid Reflux / Gastro Oesophageal Reflux Disease1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1CompletedTreatmentHeartburn1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentNeoplasms, Malignant1
1RecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis / Sickle Cell Disorders1
1TerminatedSupportive CareCancers / Malignancies, Hematologic / Malignant Lymphomas / Malignant Solid Tumours / Multiple Myeloma (MM) / Neoplasms Metastasis / Pain / Tumors / Unresectable Malignant Neoplasm1
1Unknown StatusDiagnosticAdjunct to general anesthesia therapy1
1, 2Unknown StatusTreatmentPneumonia1
2CompletedOtherBowel preparation therapy1
2CompletedPreventionCardiac Surgery and Cardiopulmonary Bypass1
2CompletedPreventionContrast Induced Nephropathy (CIN)2
2CompletedPreventionKidney Injury1
2CompletedPreventionRadiographic Contrast Agent Nephropathy1
2CompletedTreatmentAcute Kidney Injury (AKI) / Congenital Heart Disease (CHD)1
2CompletedTreatmentAnaesthesia therapy / Local Infiltration1
2CompletedTreatmentCardiac Arrest / Metabolic Acidosis1
2CompletedTreatmentImpaired Renal Function / Oliguria / Systemic Inflammatory Response Syndrome (SIRS)1
2CompletedTreatmentOral Hygiene1
2Not Yet RecruitingDiagnosticKidney Transplant; Complications1
2Not Yet RecruitingTreatmentCancers / Central Venous Catheterization1
2RecruitingTreatmentChronic Kidney Disease (CKD)1
2RecruitingTreatmentHead and Neck Carcinoma / Oral Mucositis1
2TerminatedTreatmentAcute Kidney Injury (AKI)1
2, 3CompletedPreventionContrast Induced Nephropathy (CIN)1
2, 3CompletedTreatmentChronic Kidney Disease (CKD)1
2, 3CompletedTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
2, 3TerminatedPreventionCardiopulmonary Bypass / Surgery, Cardiac1
2, 3Unknown StatusDiagnosticDetection of the Correct Position of Intravenous Line1
2, 3Unknown StatusDiagnosticDrug Extravasation / Infiltration1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableColonoscopy1
3CompletedNot AvailableContrast Induced Nephropathy (CIN) / Kidney Diseases1
3CompletedNot AvailableGastric Acid / Human Experimentation2
3CompletedNot AvailableIntragastric Acidity1
3CompletedNot AvailableLocal Anesthesia2
3CompletedDiagnosticBowel Preparation for Colonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedOtherBowel Cleansing Efficacy / Unrecognized Condition1
3CompletedPreventionChronic Kidney Disease (CKD)1
3CompletedPreventionRenal Failure1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedTreatmentCataracts2
3CompletedTreatmentColonoscopy1
3CompletedTreatmentHuman Experimentation1
3CompletedTreatmentMalignant Neoplasm of Colon1
3CompletedTreatmentOccasional Constipation1
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingOtherDigestive System Diseases1
3RecruitingPreventionAcute Kidney Injury (AKI) / Contrast media reaction1
3RecruitingTreatmentBowel Preparation Before Colonoscopy1
3RecruitingTreatmentHealthy Volunteers1
3RecruitingTreatmentMetabolic Acidosis1
3TerminatedPreventionContrast Induced Kidney Injury1
3TerminatedPreventionHypopharynx Cancer / Oropharynx Cancers1
3Unknown StatusDiagnosticColonoscopy1
3Unknown StatusPreventionAcute Renal Failure (ARF)2
3Unknown StatusPreventionChronic Kidney Disease (CKD)1
4CompletedNot AvailableColonoscopy1
4CompletedNot AvailableNormal Healthy Subject Population1
4CompletedDiagnosticAnatomic renal artery stenosis / Chronic Kidney Disease (CKD) / Pulmonary Cancer / Pulmonary Embolism (PE)1
4CompletedPreventionAcute Kidney Injury (AKI)1
4CompletedPreventionContrast Induced Acute Kidney Injury1
4CompletedPreventionContrast Induced Nephropathy (CIN)2
4CompletedPreventionContrast media reaction / Kidney Diseases1
4CompletedPreventionEmergent Coronary Procedure1
4CompletedPreventionMarginal Ulcers1
4CompletedPreventionPulmonary Embolism (PE) / Radiographic Contrast Agent Nephropathy1
4CompletedPreventionProphylaxis of Contrast-induced nephropathy1
4CompletedSupportive CareEnd-Stage Renal Disease (ESRD)1
4CompletedSupportive CarePain1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentContrast Induced Nephropathy (CIN)1
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Diabetic Kidney Disease / Diabetic Nephropathies1
4CompletedTreatmentErosive Esophagitis(EE)1
4CompletedTreatmentHeartburn1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentPreparation for Colonoscopy1
4CompletedTreatmentSubjets Requiring a Colonoscopy1
4Enrolling by InvitationDiagnosticColonoscopy1
4Enrolling by InvitationPreventionOral Mucositis1
4Enrolling by InvitationTreatmentLocal Anesthesia1
4Not Yet RecruitingDiagnosticBowel Preparation Solutions1
4Not Yet RecruitingHealth Services ResearchColorectal Cancers1
4RecruitingPreventionAcute Kidney Injury (AKI) / Aortic Valve Disorder / Chronic Kidney Disease (CKD) / Contrast Induced Nephropathy (CIN)1
4RecruitingTreatmentVaricosities of the great saphenous vein1
4TerminatedPreventionAcute Renal Failure (ARF) / Contrast Media1
4Unknown StatusHealth Services ResearchColonoscopy1
4Unknown StatusTreatmentContrast Induced Nephropathy (CIN)1
4Unknown StatusTreatmentSudden Cardiac Arrest1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedDiagnosticDiabetes Mellitus (DM)1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionAcute Renal Failure Contrast Nephropathy1
Not AvailableCompletedPreventionContrast Induced Nephropathy (CIN)1
Not AvailableCompletedPreventionDysglycaemia / Insulin Resistance / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentCardiac Arrest1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Renal Insufficiency,Chronic1
Not AvailableCompletedTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableNot Yet RecruitingTreatmentAcute Gouty Arthritis / Asymptomatic Hyperuricemia1
Not AvailableNot Yet RecruitingTreatmentKidney Transplant; Complications / Metabolic Acidosis1
Not AvailableRecruitingDiagnosticBowel preparation therapy1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableRecruitingTreatmentChronic Kidney Disease (CKD) / Metabolic Acidosis1
Not AvailableRecruitingTreatmentHealthy Volunteers1
Not AvailableTerminatedPreventionContrast Induced Nephropathy (CIN)1
Not AvailableTerminatedSupportive CareNeoplasm Related Pain (Acute) (Chronic)1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableUnknown StatusDiagnosticPreserving Kidney Function in People Who Are at High Risk of Developing Contrast-induced Nephropathy1
Not AvailableUnknown StatusTreatmentEsophagus, Barrett / Reflux, Gastroesophageal1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy / Liver Cirrhosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alaven Pharmaceutical
  • Alcon Laboratories
  • American Regent
  • Amphastar Pharmaceuticals
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • B. Braun Melsungen AG
  • C.O. Truxton Inc.
  • Cardinal Health
  • Claris Lifesciences Inc.
  • Concord Labs
  • Consolidated Medical Imaging
  • Cura Pharmaceutical Co. Inc.
  • Dispensing Solutions
  • Fresenius Kabi AB
  • General Injectables and Vaccines Inc.
  • Hospira Inc.
  • Humco
  • Luitpold Pharmaceuticals Inc.
  • Mckesson Corp.
  • Mylan
  • Norwich Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prasco Labs
  • QOL Medical
  • Sandhills Packaging Inc.
  • Santarus Inc.
Dosage forms
FormRouteStrength
LiquidTopical50 mg/1mL
LiquidTopical5 g/100g
Tablet, effervescentOral
Powder, for solutionIntraocular
LiquidOral525 mg/15mL
LiquidTopical5 g/100mL
PowderOral100 %
Powder, for solutionHemodialysis
Kit; powder, for solution; tablet, delayed releaseOral
LiquidHemodialysis81.25 g
LiquidHemodialysis72 g
LiquidHemodialysis80.68 g
SolutionHemodialysis80.7 g
SolutionHemodialysis
SolutionHemodialysis81.3 g
LiquidHemodialysis
PowderHemodialysis1250 g
PowderHemodialysis720 g
Kit; powder, for solutionHemodialysis
Powder, for solutionHemodialysis750 g
Powder, for solutionHemodialysis900 g
Granule, effervescentOral1.02 g/5g
Granule, effervescentOral1.8 g
Granule, effervescentOral269 mg
GranuleOral
Kit; solutionIntraocular
LiquidIntravenous
SuppositoryRectal
Granule, effervescentOral
KitInfiltration; Intramuscular; Intravenous
Powder, for solutionNasogastric
Powder, for solutionNasogastric; Oral
Kit
PowderNasal
PowderOral2.6 g/2.6g
PowderOral
LiquidOral25 mg/1mL
InjectionIntrathecal
Powder, for solutionOral1 g/1g
Powder, for solutionOral
PowderTopical165 g/300g
KitOral
PowderHemodialysis6 kg
Powder, for solutionHemodialysis650 g
Kit; solutionIntraocular; Irrigation
Injection, solutionIntravenous0.2 g/5mL
SolutionOral
Liquid; mouthwashOral
SolutionIntravenous
SolutionHemodialysis; Intravenous
InjectionIntravenous
KitDental
Powder, for solutionNasal
TabletOral
InjectionIntravenous84 mg/1mL
InjectionParenteral42 mg/1mL
InjectionParenteral84 mg/1mL
Injection, solutionIntravenous1 meq/1mL
Injection, solutionIntravenous42 mg/1mL
Injection, solutionIntravenous44.6 meq/50mL
Injection, solutionIntravenous75 mg/1mL
Injection, solutionIntravenous84 mg/1mL
PowderOral; Topical100 %
SolutionIntravenous42 mg/1mL
SolutionParenteral84 mg/1mL
TabletOral325 mg/1
TabletOral650 mg/1
Tablet, orally disintegratingOral650 mg/1
TabletOral648 mg/1
TabletOral324 mg/1
LiquidIntravenous50 mg
SolutionIntravenous5 g
PowderOral1 g/1g
PowderOral2.616 g/2.616g
Powder, for solutionHemodialysis672 g
LiquidIntravenous42 mg
LiquidIntravenous75 mg
LiquidIntravenous84 mg
SolutionIntravenous75 mg
SolutionIntravenous4.2 g
SolutionIntravenous42 mg
SolutionIntravenous84 mg
TabletOral300 mg
TabletOral600 mg
PowderHemodialysis650 g
PowderHemodialysis
Powder, for solutionHemodialysis1100 g
Powder, for solutionHemodialysis760 g
CapsuleOral
CreamTopical50 mg/1g
LiquidOral
Capsule, gelatin coatedOral
PowderOral1000 mg/1g
KitNasal
Granule, for solutionNasal
Powder, for suspensionOral
Tablet, chewableOral
Prices
Unit descriptionCostUnit
Golytely 236 gm Solution28.0USD bottle
Colyte 240 gm Solution26.0USD bottle
Golytely 227.1 gm Solution Packet21.85USD packet
Colyte-Flavored 240 gm Solution18.17USD bottle
Elliotts b solution ampule4.71USD ml
Sodium bicarb 4.2% vial1.45USD ml
Neut 4% vial0.92USD ml
Bss plus eye solution0.2USD ml
Sodium bicarb 650 mg tablet0.07USD tablet
Antacid 650 mg tablet0.05USD tablet
Antacid 325 mg tablet0.04USD tablet
Sodium bicarb 325 mg tablet0.04USD tablet
Sodium bicarb 7.5% vial0.04USD ml
Sodium bicarbonate powder0.03USD g
Sodium bicarb 8.4% vial0.02USD ml
Sodium bicarbonate 5% inj0.02USD ml
Colyte with flavor packets0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
USRE45198No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US5945449No1997-10-312017-10-31Us
US7300674No2003-03-042023-03-04Us
US7291324No2002-10-222022-10-22Us
US5840737No1996-07-152016-07-15Us
US6780882No1996-07-152016-07-15Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes around 50 °CNot Available
water solubility1E+005 mg/L (at 25 °C)MERCK INDEX (1996)
pKa6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility764.0 mg/mLALOGPS
logP-0.06ALOGPS
logP0.25ChemAxon
logS0.96ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity20.34 m3·mol-1ChemAxon
Polarizability3.86 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9292
Blood Brain Barrier+0.936
Caco-2 permeable-0.5321
P-glycoprotein substrateNon-substrate0.8785
P-glycoprotein inhibitor INon-inhibitor0.9903
P-glycoprotein inhibitor IINon-inhibitor0.9931
Renal organic cation transporterNon-inhibitor0.9563
CYP450 2C9 substrateNon-substrate0.8326
CYP450 2D6 substrateNon-substrate0.9017
CYP450 3A4 substrateNon-substrate0.8144
CYP450 1A2 substrateNon-inhibitor0.9053
CYP450 2C9 inhibitorNon-inhibitor0.9337
CYP450 2D6 inhibitorNon-inhibitor0.9401
CYP450 2C19 inhibitorNon-inhibitor0.9461
CYP450 3A4 inhibitorNon-inhibitor0.9774
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9911
Ames testNon AMES toxic0.9285
CarcinogenicityNon-carcinogens0.5181
BiodegradationReady biodegradable0.9636
Rat acute toxicity1.9204 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Non-inhibitor0.9866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbonate salt / Carbonic acid / Organic alkali metal salt / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic sodium salt / Organic salt / Organooxygen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
one-carbon compound, organic sodium salt (CHEBI:32139)

Targets

1. Hydrogen ions
Kind
Small molecule
Organism
Not Available
Pharmacological action
Yes
Actions
Neutralizer
References
  1. Nudel DB, Peterson BJ, Buckley BJ, Kaplan NA, Weinhaouse E, Gootman N: Comparative effects of bicarbonate and dichloroacetate in newborn swine with hypoxic lactic acidosis. Dev Pharmacol Ther. 1990;15(2):86-93. [PubMed:1964114]
  2. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C: Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001890. [PubMed:17253467]
  3. Balali-Mood M, Balali-Mood K: Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med. 2008 Jan;11(1):65-89. [PubMed:18154426]
  4. Vaughan-Jones RD, Spitzer KW: Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002;80(5):579-96. [PubMed:12440699]
  5. Levraut J, Giunti C, Ciebiera JP, de Sousa G, Ramhani R, Payan P, Grimaud D: Initial effect of sodium bicarbonate on intracellular pH depends on the extracellular nonbicarbonate buffering capacity. Crit Care Med. 2001 May;29(5):1033-9. [PubMed:11378618]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate in...
Gene Name
SLC4A4
Uniprot ID
Q9Y6R1
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 1
Molecular Weight
121459.38 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry. Regulates intracellular pH and may play a role in bicarbonate salvage in secretory epithelia. ...
Gene Name
SLC4A7
Uniprot ID
Q9Y6M7
Uniprot Name
Sodium bicarbonate cotransporter 3
Molecular Weight
136042.595 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates electroneutral sodium- and carbonate-dependent chloride-HCO3(-) exchange with a Na(+):HCO3(-) stoichiometry of 2:1. Plays a major role in pH regulation in neurons. May be involved in cell ...
Gene Name
SLC4A8
Uniprot ID
Q2Y0W8
Uniprot Name
Electroneutral sodium bicarbonate exchanger 1
Molecular Weight
122936.66 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Mediates sodium- and bicarbonate-dependent electrogenic sodium bicarbonate cotransport, with a Na(+):HCO3(-) stoichiometry of 2:1. May have a housekeeping function in regulating the pH of tissues i...
Gene Name
SLC4A5
Uniprot ID
Q9BY07
Uniprot Name
Electrogenic sodium bicarbonate cotransporter 4
Molecular Weight
126254.04 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium:bicarbonate symporter activity
Specific Function
Electrogenic sodium/bicarbonate cotransporter in exchange for intracellular chloride. Plays an important role in regulating intracellular pH (By similarity).
Gene Name
SLC4A10
Uniprot ID
Q6U841
Uniprot Name
Sodium-driven chloride bicarbonate exchanger
Molecular Weight
125945.115 Da
References
  1. Bernardo AA, Bernardo CM, Espiritu DJ, Arruda JA: The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60. [PubMed:17071329]
  2. Kurtz I, Petrasek D, Tatishchev S: Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90. [PubMed:15014910]
  3. Soleimani M: Functional and molecular properties of Na+:HCO-3 cotransporters (NBC). Minerva Urol Nefrol. 2003 Jun;55(2):131-40. [PubMed:12847417]
  4. Soleimani M: Na+:HCO3- cotransporters (NBC): expression and regulation in the kidney. J Nephrol. 2002 Mar-Apr;15 Suppl 5:S32-40. [PubMed:12027220]

Drug created on July 08, 2007 10:59 / Updated on September 18, 2018 23:02